About Carcinotech
Carcinotech is a company based in Edinburgh (United Kingdom) founded in 2018. It operates as a B2B. Carcinotech has raised $7.35 million across 4 funding rounds from investors including Santander UK, Scottish Enterprise and Maven Capital Partners. The company has 1 employees as of June 30, 2021. Carcinotech offers products and services including Biopsy Sourcing, 3D Tumor Development, and Oncology Assays. Carcinotech operates in a competitive market with competitors including Biocytogen, Applied StemCell, GenOway, Newcells Biotech and Interius Biotherapeutics, among others.
- Headquarter Edinburgh, United Kingdom
- Employees 1 as on 30 Jun, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Carcinotech Ltd
- Date of Incorporation 31 Jul, 2018
- Jurisdiction EDINBURGH, MIDLOTHIAN, SCOTLAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$7.35 M (USD)
in 4 rounds
-
Latest Funding Round
$5.3 M (USD), Seed
Jan 29, 2024
-
Investors
Santander UK
& 11 more
-
Employee Count
1
as on Jun 30, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Carcinotech
Carcinotech offers a comprehensive portfolio of products and services, including Biopsy Sourcing, 3D Tumor Development, and Oncology Assays. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Sourcing tumor biopsies for oncology research and development.
Creating 3D-printed tumor models for drug testing applications.
Conducting assays to evaluate cancer treatments and therapies.
Unlock access to complete
Funding Insights of Carcinotech
Carcinotech has successfully raised a total of $7.35M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $5.3 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Seed — $5.3M
- First Round First Round
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Seed - Carcinotech | Valuation | Eos Advisory , Investing Women | |
| Apr, 2022 | Amount | Seed - Carcinotech | Valuation | Tricapital | |
| Aug, 2020 | Amount | Seed - Carcinotech | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Carcinotech
Carcinotech has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Santander UK, Scottish Enterprise and Maven Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in science and technology is managed by Eos.
|
Founded Year | Domain | Location | |
|
Early-stage investment is provided to promising Scottish entrepreneurs.
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on social impact companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Carcinotech
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Carcinotech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Carcinotech Comparisons
Competitors of Carcinotech
Carcinotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biocytogen, Applied StemCell, GenOway, Newcells Biotech and Interius Biotherapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Integrated solutions for next-generation antibody drug development are provided.
|
|
| domain | founded_year | HQ Location |
Provider of animal and cell line models as tools for drug discovery and diagnostics
|
|
| domain | founded_year | HQ Location |
Provider of transgenic rodent models and customized cell lines for preclinical development
|
|
| domain | founded_year | HQ Location |
Induced pluripotent stem cell-derived organoid models are developed for research.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating multiple diseases
|
|
| domain | founded_year | HQ Location |
Cell-based assays and 3D microtissues for drug screening are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Carcinotech
Frequently Asked Questions about Carcinotech
When was Carcinotech founded?
Carcinotech was founded in 2018.
Where is Carcinotech located?
Carcinotech is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Is Carcinotech a funded company?
Carcinotech is a funded company, having raised a total of $7.35M across 4 funding rounds to date.
How many employees does Carcinotech have?
As of Jun 30, 2021, the latest employee count at Carcinotech is 1.
What does Carcinotech do?
Carcinotech specializes in preclinical oncology services, utilizing 3D-bioprinted, patient-derived tumors to advance drug development and personalized treatments. They offer biopsy sourcing, tumor development, and oncology assays to support early drug discovery and testing. Based in the United Kingdom, they collaborate with biotech organizations and researchers to enhance cancer research efficiency and accuracy.
Who are the top competitors of Carcinotech?
Carcinotech's top competitors include Biocytogen, Applied StemCell and Newcells Biotech.
What products or services does Carcinotech offer?
Carcinotech offers Biopsy Sourcing, 3D Tumor Development, and Oncology Assays.
Who are Carcinotech's investors?
Carcinotech has 12 investors. Key investors include Santander UK, Scottish Enterprise, Maven Capital Partners, The University of Edinburgh, and Eos.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.